This trial is looking at whether having hormone therapy for 2 weeks before and 2 weeks after surgery helps postmenopausal women with breast cancer. The trial is supported by Cancer Research UK.
The first treatment for early breast cancer is usually surgery. After surgery, women who have hormone receptor positive breast cancer will have hormone therapy as part of their treatment. Most women have hormone therapy for at least 5 years. This helps to reduce the risk of breast cancer coming back.
Drugs called aromatase inhibitors are a type of hormone therapy for women who have gone through the menopause. In this trial, doctors want to find out if having an aromatase inhibitor for 2 weeks before and after surgery, as well as standard hormone therapy, helps reduce the risk of breast cancer coming back even more.
The researchers will also look at testing the cancer cells to see if there are any changes after a short course of hormone therapy. In the future, this may help doctors to work out which treatment is best for each individual patient. The aims of the trial are to
- See if 4 weeks of an aromatase inhibitor at the time of surgery helps to reduce the risk of early breast cancer coming back
- Find out if testing the cancer cells after 2 weeks of hormone therapy can help to predict how well a woman will respond to treatment
For more information about this trial go to :
OPTIMA is a patient driven clinical study for people with hormone sensitive early breast cancer.
On the 25th March we held an interactive talk and discussion on immunology.
The talk was given by Dr Edd James, Cancer Immunologist from the university of Southampton. The tallk is now available on YouTube - click here to listen.
Long Term Survivor Study
Continuum Life Sciences are looking for volunteers who have survived aggressive, difficult to treat cancer against all odds to take part in their Long-Term Survivor of Cancer Study. For more information and how you can join go to their website.
Save the planet and donate to ICPV - send ecards go tour Fundraising page for mor information.
FAST-Forward Trial Results
A one-week course of radiotherapy in fewer but larger daily doses was found to be as safe and effective as standard three-week therapy for women following surgery for early stage breast cancer. Trial results now published. Two ICPV members provided the PPI for this key trial. Full details can be found on the ICR Website.
ICPV Brighton Summer School Aug 2019
ICPV was once again hosted by SHORE-C at the University of Sussex. Click here for more info.
San Antonio Breast Cancer Symposium, 2018
ICPV member Pat Fairbrother attended this event on an Alamo Foundation Scholarship. Click here to read her review.
Gap Analysis in Breast Surgery Published
The 2013 Breast Cancer Campaign gap analysis established breast cancer research priorities without a specific focus on surgical research or the role of surgeons on breast cancer research. This Review aims to identify opportunities and priorities for research in breast surgery to complement the 2013 gap analysis. Click here for more information
ICPV Review 2018
We have at last published a new edition of our review. This was achieved by a grant from Novartis. Click here for more information.
Award for ICPV Member
Many congratulations to ICPV member Margaret Grayson. On 21 April 2018 she received the Iris Colvin Lifetime Achievement Award for Health, presented by the Women’s Forum of Northern Ireland. This is very well deserved for her tireless work in furthering cancer research especially in Northern Ireland.
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.